Holen Sie sich die Stockscreener-App
1.02
4.08%
0.04
Handel nachbörslich:
1.01
-0.01
-0.98%
20 20 Biolabs Inc Aktie (AIDX) Neueste Nachrichten
No Analysis Provided - StocksToTrade
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX - Finviz
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Nigeria
20/20 Biolabs Engages Pcr Test Kit Developers For Ebola And Hantavirus Testing - TradingView
Lab that ran 400,000 COVID tests now preparing for Ebola, hantavirus - Stock Titan
20/20 Biolabs 2Q Loss/Shr 28c >AIDX - Moomoo
20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
20/20 Biolabs (AIDX) posts lower Q1 revenue and deeper loss after $5M preferred raise - Stock Titan
20/20 BioLabs reports Q1 2026 revenue $0.4M, net loss $2.17M, cash $4.2M - TradingView
Q1 2026: 20/20 BioLabs (AIDX) revenue declines as cash rises on $5M raise - Stock Titan
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - The Manila Times
Press Release: 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - Moomoo
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout
Maxim Group Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
20/20 Biolabs (AIDX) delays 10-Q filing; expects 5-day extension - Stock Titan
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - ChartMill
20/20 Biolabs, Inc.Common Stock (NQ: AIDX - FinancialContent
AIDX | 20/20 Biolabs, Inc. Common FinancialsIncome Statement - Quiver Quantitative
USC inks licensing agreement for prostate cancer screening tool - University of South Carolina
20/20 BioLabs Licenses Patented Algorithm from University of South Carolina for Early Detection of Aggressive Prostate Tumors - Quiver Quantitative
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - The Manila Times
New PSA algorithm uses repeat blood tests to flag high-risk prostate tumors early - Stock Titan
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
AIDX: 20/20 Biolabs Inc.Brokerage Recommendations Chart - Zacks Investment Research
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
A. G. P. Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $1.46 - Moomoo
20/20 Biolabs Unchanged on News - Baystreet.ca
How 20/20 Biolabs (AIDX) integrates its acquisitions | AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsViral Momentum Stocks - newser.com
AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsUnderperform - newser.com
20/20 Biolabs Inc. (AIDX) Gross Margin (TTM) - Zacks Investment Research
Is 20/20 Biolabs (AIDX) stock a strong buy |Bond Issuance - newser.com
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers - Proactive financial news
20/20 Biolabs (NASDAQ: AIDX) cuts warrant price, registers 15.16M shares - Stock Titan
Warrant strike cut to $2.25 as 20/20 Biolabs (NASDAQ: AIDX) registers 10.1M shares - Stock Titan
Streeterville warrant repricing at 20/20 Biolabs (NASDAQ: AIDX) drops strike - Stock Titan
AIDX (20/20 Biolabs) highlights rising clinical test adoption as core growth driver in latest quarterly earnings.Community Trade Ideas - Newser
How to Value 20/20 Biolabs (AIDX) Stock (Technical Strength) 2026-04-22Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX | 20/20 Biolabs, Inc. Common Insider Trading - Quiver Quantitative
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
1.27%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):